Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies

Visit https://www.peervoice.com/EUQ860 to view the entire programme with slides. After completing “Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies”, participants will be able to: Explain the implications of passive and adaptive immunity to AAV on the potential for patient eligibility for AAV gene therapy; Use anti-AAV antibody titres to identify eligibility for AAV gene transfer therapy in patients with a rare genetic neuromuscular disease; and Identify which patients who have a rare genetic neuromuscular disease and an initial anti-AAV9 antibody titre above the threshold for eligibility for gene therapy should be retested to assess for titre waning.